Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia



Navaratnam, Kate, Alfirevic, Ana ORCID: 0000-0002-2801-9817, Jorgensen, Andrea ORCID: 0000-0002-6977-9337 and Alfirevic, Zarko ORCID: 0000-0001-9276-518X
(2018) Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 221. pp. 144-150.

[img] Text
EARTH accepted.pdf - Author Accepted Manuscript

Download (577kB)

Abstract

<h4>Objectives</h4>Low-dose aspirin is recommended for prevention of pre-eclampsia in high-risk pregnant women. Current doses provide a conservative risk reduction and some individuals demonstrate 'aspirin non-responsiveness', with insufficient antiplatelet effects. We aimed to determine if aspirin non-responsiveness could be identified in women at high risk of pre-eclampsia and assess for potential associations with placentally-mediated adverse outcomes.<h4>Study design</h4>Prospective cohort study. 180 women at high-risk of pre-eclampsia, by NICE criteria, prescribed 75 mg dispersible aspirin daily were recruited from antenatal clinics of Liverpool Women's Hospital between 17/01/14 and 31/03/16. Platelet function (Multiplate™ impedance aggregometry, VerifyNow™ and 11-dehydrothromboxane B<sub>2</sub>) and aspirin metabolites (nuclear magnetic resonance and liquid chromatography mass spectrometry) were assessed at 5 + <sup>0</sup>-20 + <sup>6</sup> and 33 + <sup>0</sup>-35 + <sup>6</sup> weeks. Pearson's chi-square test was used to assess for associations between longitudinal response to aspirin and (1) any pre-eclampsia (2) composite adverse placentally-mediated outcome (one, or combination of pre-eclampsia, placental abruption, IUGR and perinatal mortality). A Bonferroni correction was applied to correct for multiple analyses.<h4>Results</h4>180 women were recruited, there were 4 withdrawals and no women were lost to follow-up. After 15 women delivered prior to the completion of follow-up, sufficient sample volumes for longitudinal platelet function and aspirin adherence testing were obtained from 156 women. There were no consistent aspirin non-responders in the cohort. 59% (n = 92) women exhibited normal response to aspirin, 34% (n = 53) variable response (switching response status between study visits) and in 7% (n = 11) response could not be determined as they exhibited lack of platelet response on a background of undetectable aspirin metabolites. There was no significant association between indeterminate or inconsistent (variable or indeterminate) response to aspirin and either pre-eclampsia (p = 0.59, p = 0.84) or composite outcome (p = 0.95, p = 0.65).<h4>Conclusions</h4>When platelet function was assessed with COX-specific tests that measure the antiplatelet effects of low-dose aspirin and aspirin adherence is accurately accounted for aspirin non-responsiveness was not identified in pregnant women at high-risk of pre-eclampsia. Response to aspirin was not associated with placentally-mediated adverse outcomes. The high-degree of variable and indeterminate aspirin response indicates suboptimal adherence and/or dosing are more pressing factors to address to optimise aspirin effectiveness.

Item Type: Article
Uncontrolled Keywords: Pregnancy, Pre-eclampsia, Aspirin, Aspirin resistance, Aspirin non-responsiveness
Depositing User: Symplectic Admin
Date Deposited: 15 Jan 2018 07:27
Last Modified: 13 Feb 2024 15:04
DOI: 10.1016/j.ejogrb.2017.12.052
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3016079